Stabilization of E-cadherin adhesions by COX-2/GSK3β signaling is a targetable pathway in metastatic breast cancer
Open Access
- 22 March 2023
- journal article
- research article
- Published by American Society for Clinical Investigation in JCI Insight
- Vol. 8 (6)
Abstract
Metastatic progression of epithelial cancers can be associated with epithelial-mesenchymal transition (EMT) including transcriptional inhibition of E-cadherin ( CDH1 ) expression. Recently, EM plasticity (EMP) and E-cadherin–mediated, cluster-based metastasis and treatment resistance have become more appreciated. However, the mechanisms that maintain E-cadherin expression in this context are less understood. Through studies of inflammatory breast cancer (IBC) and a 3D tumor cell “emboli” culture paradigm, we discovered that cyclooxygenase 2 (COX-2; PTGS2 ), a target gene of C/EBPδ ( CEBPD ), or its metabolite prostaglandin E2 (PGE2) promotes protein stability of E-cadherin, β-catenin, and p120 catenin through inhibition of GSK3β. The COX-2 inhibitor celecoxib downregulated E-cadherin complex proteins and caused cell death. Coexpression of E-cadherin and COX-2 was seen in breast cancer tissues from patients with poor outcome and, along with inhibitory GSK3β phosphorylation, in patient-derived xenografts (PDX) including triple negative breast cancer (TNBC).Celecoxib alone decreased E-cadherin protein expression within xenograft tumors, though CDH1 mRNA levels increased, and reduced circulating tumor cell (CTC) clusters. In combination with paclitaxel, celecoxib attenuated or regressed lung metastases. This study has uncovered a mechanism by which metastatic breast cancer cells can maintain E-cadherin–mediated cell-to-cell adhesions and cell survival, suggesting that some patients with COX-2 + /E-cadherin + breast cancer may benefit from targeting of the PGE2 signaling pathway.Keywords
All Related Versions
Funding Information
- Instituto Nacional de Cancerología (Intramural Program)
- METAvivor Research and Support, Inc (n/a)
- The State of Texas Rare and Aggressive Breast Cancer Program (n/a)
- BC Research Foundation (BCRF-20-048)
- METAvivor (U01CA217846)
This publication has 84 references indexed in Scilit:
- Characterization of cell lines derived from breast cancers and normal mammary tissues for the study of the intrinsic molecular subtypesBreast Cancer Research and Treatment, 2013
- Mammosphere Formation in Breast Carcinoma Cell Lines Depends upon Expression of E-cadherinPLOS ONE, 2013
- COX-2 regulates E-cadherin expression through the NF-κB/Snail signaling pathway in gastric cancerInternational Journal of Molecular Medicine, 2013
- The Many Faces of C/EBPδ and their Relevance for Inflammation and CancerInternational Journal of Biological Sciences, 2013
- COX-2 activation is associated with Akt phosphorylation and poor survival in ER-negative, HER2-positive breast cancerBMC Cancer, 2010
- A stromal gene signature associated with inflammatory breast cancerInternational Journal of Cancer, 2007
- Regulation of intracellular cyclooxygenase levels by gene transcription and protein degradationProgress in Lipid Research, 2007
- C/EBPδ is a crucial regulator of pro-apoptotic gene expression during mammary gland involutionDevelopment, 2005
- Role of E‐cadherins in development of lymphatic tumor emboliCancer, 2003
- Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implicationsProceedings of the National Academy of Sciences of the United States of America, 2001